Skip to main content
PMC home page
Diabetes Therapy logoLink to Diabetes Therapy
. 2018 Dec 5;10(1):325–326. doi: 10.1007/s13300-018-0543-9

Correction to: Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons

Chakrapani Balijepalli 1,✉, Rohan Shirali 1, Prashanth Kandaswamy 2, Anastasia Ustyugova 2, Egon Pfarr 2, Søren S Lund 2, Eric Druyts 1
PMCID: PMC6349291  PMID: 30519858

Correction to: Diabetes Ther (2018) 9:1491–1500 10.1007/s13300-018-0456-7

In the original publication, Figure 3 was incorrectly published. The authors have updated figure 3 and the corrected Fig. 3 is given below.

Fig. 3.

Fig. 3

Open in a new tab

Plots presenting indirect comparisons of empagliflozin versus other glucose-lowering drugs

Open Access

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Articles from Diabetes Therapy are provided here courtesy of Springer

RESOURCES